Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer

Total Neoadjuvant Therapy With mFOLFOX and Short-course Radiation in Resectable Rectal Cancer is a phase 2, interventional study registered as NCT04643366 by Virginia Commonwealth University, with a registry enrolment figure of 64 participants, started 2021-01-28 and due to reach its primary completion in 2030-01-31. Interventions recorded: Chemotherapy; Radiation Therapy. Conditions listed: Rectal Cancer. Primary outcome: Three-year disease free survival (DFS). Colorectal eligibility wording from the registry: "* Pathologic diagnosis of adenocarcinoma of the rectum (diagnosis by tissue biopsy) within 90 days prior to registration". Sites: United States. No results are recorded here; the registry entry is the source.